Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
NCT04331119Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jul 2020
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in T-cell lymphoma, sponsored by Washington University School of Medicine. Primary endpoint: Progression-free survival at 2 years. Started Jul 2020; status: terminated.
02
Drugs
duvelisib
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT04331119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04331119.